Many years ago the Apotex Group of Companies accepted the challenge to build a world class Canadian-owned pharmaceutical company with a commitment to excellence. This includes our Research, Development, Production and Distribution which all fits together for the most important objective, "Service to our Customers" in the quest of advancing generics.
We have done this by investing in our future by building the best facilities, committing over $2 billion for R&D over the next 10 years, improving our internal systems with SAP and other innovative technologies, and by supporting and strengthening our human resources.
Customer satisfaction begins with employee satisfaction.
A commitment to clear, frequently repeated quality goals - followed up with continuous measurement of progress against those goals - forms the foundation of the Apotex Group of Companies'. We know that quality is absolutely the only road to a satisfied customer at the end of each transaction.
As consolidation in the pharmaceutical industry continues and the Canadian-owned companies disappear, it is important to understand what the Apotex Group is trying to do in the development of generic medicines, including generic biosimilars. The commitment is to a complete product line to meet world pharmaceutical needs at affordable prices.
The reasons for doing all of this are simple - we are not just any pharmaceutical company, we are Canada's pharmaceutical company that is advancing the use of generics worldwide.
Jack M. Kay
President & C.O.O.